Company intelligence / Profile preview
GEM Biosciences
United Statesgembiosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GEM Biosciences has developed a proprietary platform for delivering therapeutic levels of carbon monoxide directly to sites of wounds and inflammation. This approach aims to enhance the effectiveness and safety profile of CO therapy in clinical practice. No published human clinical results are available as of now.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Gas-based therapy (specifically carbon monoxide delivery)Device/Material-based drug delivery
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
None publicly disclosed as of June 2025.
Beyond the preview
Go deeper on GEM Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEM Biosciences.